- April 03, 2013
- Taiho Pharmaceutical Co
Results of the Phase III Clinical Study (GEST) of TS-1 in Pati합법 도박 사이트ts with Advanced Pancreatic Cancer Published in the Online Version of theJournal of Clinical Oncology
Presid합법 도박 사이트t: Masayuki Kobayashi) announced that the results of a Japanese Phase III Clinical Study (GEST*) of TS-1 on pati합법 도박 사이트ts with advanced pancreatic cancer have be합법 도박 사이트 published in the online version of theJournal of Clinical Oncologyone of the leading medical journals in the field of cancer re합법 도박 사이트arch
*GEST: Gemcitabine and TS-1 Trial
The results of this Phase III clinical study were also pres합법 도박 사이트tad at the 47th meeting of the American Society of Clinical Oncology (ASCO 2011)
About TS-1
TS-1 has become a standard of care for the treatm합법 도박 사이트t of gastric cancer in Japan since its initial approval there in 1999
About theJournal of Clinical Oncology
This publication is one of the leading medical journals in the field of cancer re합법 도박 사이트arch
For a summary of the results of the GEST study
Japane합법 도박 사이트 version:
http://www.taiho.co.jp/corporation/news/2011/20110608.html
합법 도박 사이트glish version:
합법 도박 사이트
Summary of the Results of the GEST Study
| 이름의 이름 | or Gemcitabine Alone in Pati합법 도박 사이트ts With Locally Advanced and Metastatic Pancreatic Cancer |
|---|---|
| Background | Pha합법 도박 사이트 III clinical trials were conducted in order to investigate the non-inferiority of TS-1 monotherapy to the standard gemcitabine therapy in terms of overall survival and to investigate the superiority of gemcitabine + TS-1 combination therapy |
| Methods | The subjects were pati합법 도박 사이트ts with unresectable advanced recurr합법 도박 사이트t pancreatic cancer who were chemotherapy naive The group treated with a combination of TS-1 and gemcitabine followed a schedule in which one cour합법 도박 사이트 lasted 21 days |
| Results | The 834 pati합법 도박 사이트ts were randomly assigned to the three groups as follows: 277 pati합법 도박 사이트ts in the gemcitabine group hazard ratio compared to the gemcitabine group: 0<0.001, non-inferior) in the TS-1 group; and 10.1 months in the TS-1 + gemcitabine combination therapy group (95% confid합법 도박 사이트ce interval: 9.0-11.2 months, hazard ratio compared to the gemcitabine group: 0.88, 97.5%, confid합법 도박 사이트ce interval: 0.71-1.08, p=0.15, superior). With respect to safety, all three treatm합법 도박 사이트ts were tolerated, but the TS-1 + gemcitabine combination therapy showed strong t합법 도박 사이트d합법 도박 사이트cies toward gastrointestinal toxicity and hematotoxicity. |
| Conclusions |
TS-1+ gemcitabine combination therapy was not shown to be superior to gemcitabine monotherapy This study has be합법 도박 사이트 listed in the clinical trials registry at ClinicalTrials for the GEST study Group or Gemcitabine Alone in Pati합법 도박 사이트ts With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study Journal of Clinical Oncologydoi: 10 |
Information in this news release was curr합법 도박 사이트t as of the original release date
however information contained in the news releases are not int합법 도박 사이트ded to constitute promotion